0001540159
false
00-0000000
0001540159
2023-10-12
2023-10-12
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event
reported): October 12, 2023
Edesa Biotech, Inc.
(Exact Name of Registrant as Specified
in its Charter)
British Columbia, Canada |
|
001-37619 |
|
N/A |
(State or Other Jurisdiction
of Incorporation) |
|
(Commission
File Number) |
|
(IRS Employer
Identification No.) |
|
|
|
100 Spy Court
Markham, Ontario, Canada L3R 5H6 |
(Address of Principal Executive Offices) |
(289)
800-9600
Registrant’s telephone number, including
area code
N/A
(Former name or former address, if
changed since last report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):
¨ | Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| |
¨ | Soliciting material pursuant
to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| |
¨ | Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| |
¨ | Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
|
Trading Symbol(s) |
|
Name of exchange on which registered |
Common Shares |
|
EDSA |
|
The Nasdaq Stock Market LLC |
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ¨
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 1.01 Entry into a Material Definitive
Agreement
On October 12, 2023, Edesa Biotech Research,
Inc. (“Edesa Biotech Research”), a wholly owned subsidiary of Edesa Biotech, Inc. (the “Company”) and the
Company, as guarantor, entered into a multi-year contribution agreement (the “Agreement”) with the Government of Canada.
Pursuant to the Agreement, the Government of Canada committed up to CAD $23 million ($17 million USD) in partially repayable funding
toward (i) conducting and completing the Company’s Phase 3 clinical study of its experimental drug EB05 (paridiprubart) in
critical-care patients with Acute Respiratory Distress Syndrome (ARDS) caused by COVID-19 or other infectious agents, (ii)
submitting EB05 for governmental approvals and manufacturing scale-up, following, and subject to, completing the Phase 3 study and (iii) conducting two
non-clinical safety studies to assess the potential long-term impact of EB05 exposure (the “Project”). Edesa Biotech
Research agreed to complete the Project, which will be conducted exclusively in Canada (except as permitted otherwise under
certain circumstances), on or before December 31, 2025. The Company agreed to guarantee the complete performance and fulfillment of
Edesa Biotech Research’s obligations under the Agreement. In the event Edesa Biotech Research fails to perform or otherwise
satisfy any of its obligations related to the Agreement, the Company will become a primary obligor under the Agreement.
Of the CAD $23 million committed by the Government
of Canada under the Agreement, CAD $5.75 million is not repayable. The remaining CAD $17.25 million is conditionally repayable starting
in 2029 only if and when the Company earns gross revenue. The repayable portion would be payable over fifteen (15) years based on a percentage
rate of the Company’s annual revenue growth. The maximum amount repayable under the Agreement is 1.4 times the original repayable
amount. In addition, the Company is entitled to partial reimbursement of certain eligible expenses under the Agreement.
Under the Agreement, Edesa Biotech Research has
agreed to certain financial and non-financial covenants and other obligations in relation to the Project, including (i) the achievement
of certain headcount requirements in Canada, (ii) the maintenance of a collaboration with a Canadian research institute or post-secondary
institutions, (iii) the maintenance of certain research and development expenditures in Canada, (iv) the maintenance of inclusive hiring
practices and employee training and (v) the creation of an environmental sustainability plan. In addition, Edesa Biotech Research has
granted notice and consent rights to the Government of Canada upon certain events related to a Change in Control (as defined in the Agreement).
For the term of the Agreement, Edesa Biotech Research
must have exclusive ownership of all intellectual property (i) conceived, produced or developed in connection with the Project and (ii)
that is required for the carrying out of the Project (the “Intellectual Property”). Pursuant to the Agreement, Edesa Biotech
Research is required, subject to certain exceptions, to obtain the consent of the Government of Canada prior to granting any right or
license to any of the Intellectual Property. Furthermore, the Government of Canada may require Edesa Biotech Research to assign, transfer
or grant a license to use the Intellectual Property to the extent necessary to ensure a sufficient domestically-sourced supply of vaccines
and/or treatments in response to COVID-19 if Edesa Biotech Research is unable to ensure such a supply.
Pursuant to the Agreement, certain customary events
of default, such as the Company’s or Edesa Biotech Research’s breach of their covenants and obligations under the Agreement,
their insolvency, winding up or dissolution, and other similar events, may permit the Government of Canada to declare an event of default
under the Agreement. Upon an event of default, subject to applicable cure, the Government of Canada may exercise a number of remedies,
including suspending or terminating funding under the Agreement, demanding repayment of funding previously received and/or terminating
the Agreement.
The funding and any associated conditional repayments
are not secured by any assets of Edesa Biotech Research or the Company.
The Agreement will expire on the later of
December 31, 2042 or the date of the last repayment, unless earlier terminated, subject to certain provisions that extend three (3)
years beyond the term or early termination of the Agreement.
The foregoing description of the Agreement does
not purport to be complete and is qualified in its entirety by reference to the text of the Agreement, a copy of which will be filed with
the Company’s annual report on Form 10-K for the fiscal year ending September 30, 2023.
Item 2.03 Creation of a Direct Financial Obligation or an Obligation
under an Off-Balance Sheet Arrangement of a Registrant
The information set forth under
Items 1.01 and 8.01 is incorporated into this Item 2.03 by reference.
Item 7.01 Regulation FD Disclosure
On October 12, 2023, the Company issued a press
release announcing the execution of the Agreement. The full text of the press release is attached hereto as Exhibit 99.1.
On October 12, 2023, the Company issued a press release announcing
that it has entered into a binding commitment letter with Dr. Par Nijhawan, MD, the Company’s Chief Executive Officer and member
of the Board of Directors of the Company related to a $10 million revolving credit facility agreement. The full text of the press release
is attached hereto as Exhibit 99.2.
The information in this Current Report on Form
8-K under Item 7.01, including the information contained in Exhibits 99.1 and 99.2, is being furnished to the Securities and Exchange
Commission, and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as
amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated
by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth
by a specific reference in such filing.
Item 8.01 Other Events
On October 12, 2023, the Company announced
that it has entered into a binding commitment letter with Dr. Par Nijhawan, MD, the Company’s Chief Executive Officer and
member of the Board of Directors of the Company related to a $10 million revolving credit facility agreement. The binding commitment
letter provides for a revolving line of credit in the amount of up to $10 million, with $3.5 million available immediately upon the
execution of the definitive agreement for the credit facility. Advances under the revolving credit facility will be subject to
compliance with all applicable laws, and tied to a borrowing base consisting of eligible grant reimbursement receivables, future
potential license fee receivables and any other accounts receivable. The binding commitment letter provides for an interest rate of
the CIBC US Base-Interest Rate plus 300bps and a maturity date of March 31, 2026. The availability of the credit facility will be
subject to finalization and execution of a definitive credit agreement and related documents.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
Edesa Biotech, Inc. |
|
|
Date: October 12, 2023 |
By: |
/s/ Stephen Lemieux |
|
Name: |
Stephen Lemieux |
|
Title: |
Chief Financial Officer |
Exhibit 99.1
Edesa Biotech to Receive Up To C$23 Million
in Funding from Federal Government
TORONTO, ON / ACCESSWIRE / October 12, 2023 / Edesa Biotech, Inc. (Nasdaq:EDSA),
a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, has secured a commitment of up to C$23
million from the Government of Canada for a pivotal Phase 3 clinical study of the company’s first-in-class therapeutic candidate.
Edesa’s experimental drug, called EB05 (paridiprubart), represents
a new class of emerging therapies called Host-Directed Therapeutics (HDTs) that are designed to modulate the body's own immune response
when confronted with infectious diseases or even chemical agents. Importantly, these therapies are agnostic to the causal agent and can
be stockpiled preemptively for seasonal outbreaks and unexpected emergencies and threats.
“This project has the potential to increase survival rates, reduce
ICU costs and improve outcomes for critically ill patients,” said Par Nijhawan, MD, Chief Executive Officer of Edesa Biotech. “With
this validation and the continued support from the federal government, we believe we are in a position to accelerate research, expand
our reach to more hospitals and move another significant step closer to commercialization.”
Edesa’s current project builds on the success of a government-supported
Phase 2 clinical study completed during the pandemic which demonstrated that paridiprubart reduced mortality by 84% among critically
ill patients with a severe form of respiratory disease called Acute Respiratory Distress Syndrome (ARDS). A parallel in vitro
study at the University of Toronto also demonstrated recently that paridiprubart inhibits inflammation from influenza and other
pathogens.
“We are proud of our track record of delivering successful results
on time and on budget for our government-supported projects,” said Dr. Nijhawan. “The development of breakthrough medicines
– especially in the critical care fields – is key to building a strong biopharma sector, creating jobs and most importantly
improving patient outcomes at home and abroad. We are honored to be a part of these efforts.”
The Honorable François-Philippe Champagne, Minister of Innovation,
Science and Industry said that the Strategic Innovation Fund (SIF) funding announced today is part of the government's plan to grow a
strong and competitive life sciences sector, and ensure the nation’s readiness for future pandemics or other health emergencies.
“This project is a prime example of Canada's determination to
the development of the next generation of medicine, while creating good jobs and securing long-term economic growth,” said Minister
Champagne.
Edesa intends to use the SIF funding toward study expenses, including
hospital and physician expenditures, as well as scale-up of commercial drug product should the development program be successful. Funding
is provided under the federal government’s Strategic Innovation Fund (SIF) following a competitive review process.
Additional information regarding the funding are outlined in the company’s
Current Report on Form 8-K, which Edesa expects to file with the U.S. Securities and Exchange Commission and on the SEDAR+ system in Canada.
About ARDS
ARDS involves an exaggerated immune response leading to inflammation
and injury to the lungs that prevents the lungs from oxygenating blood and ultimately deprives the body of oxygen. For moderate to severe
cases, there are currently few meaningful treatments, other than supplemental oxygen and mechanical ventilation, and patients suffer high
mortality rates. In addition to virus-induced pneumonia, ARDS can be caused by smoke/chemical inhalation, sepsis, chest injury and other
causes. Prior to the pandemic, ARDS accounted for 10% of intensive care unit admissions, representing more than 3 million patients globally
each year.
About EB05 (Paridiprubart)
Paridiprubart is a first-in-class monoclonal antibody developed for
acute and chronic disease indications that involve dysregulated innate immune responses. This host-directed therapeutic (HDT) candidate
inhibits toll-like receptor 4 (TLR4), a key immune signaling protein that has been shown to be activated both by viruses, like SARS-CoV2,
SARS-CoV1 and Influenza, as well as in the pathogenesis of chronic autoimmune diseases.
About Phase 3 Clinical Study
Edesa’s Phase 3 study of EB05 (paridiprubart) is a multicenter,
randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of EB05 in critical-care patients. The current
protocol calls for treatment of ARDS subjects hospitalized with SARS-CoV2 infections who are on invasive mechanical ventilation, both
with and without additional organ support. The primary endpoint is the mortality rate at 28 days. In addition to SARS-CoV2 induced ARDS,
Edesa is currently exploring various approaches to evaluate EB05 in a general ARDS population.
About Edesa Biotech, Inc.
Edesa Biotech, Inc. (Nasdaq: EDSA) is a clinical-stage biopharmaceutical
company developing innovative ways to treat inflammatory and immune-related diseases. The Company’s most advanced drug candidate
is EB05 (paridiprubart), a monoclonal antibody developed for acute and chronic disease indications that involve dysregulated innate immune
responses. Edesa is currently evaluating EB05 in a Phase 3 study as a potential treatment for Acute Respiratory Distress Syndrome (ARDS),
a life-threatening form of respiratory failure. In addition, Edesa is developing an sPLA2 inhibitor, EB01 (daniluromer), as a topical
treatment for chronic Allergic Contact Dermatitis (ACD), a common occupational skin condition. The Company has also received regulatory
approval to conduct a Phase 2 trial its EB06 monoclonal antibody as a treatment for vitiligo, a life-altering autoimmune disease that
causes skin to lose its color in patches. Edesa is also planning to file an investigational new drug application for a future Phase 2
study of paridiprubart for systemic sclerosis (scleroderma), an autoimmune rheumatic disorder that causes fibrosis, (scarring/hardening)
of skin and internal organs such as the lungs, heart and kidneys. Sign up for news alerts. Connect with us on Twitter and
LinkedIn.
Edesa Forward-Looking Statements
This press release may contain forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended.
Forward-looking statements may be identified by the use of words such as "anticipate," "believe," "plan,"
"estimate," "expect," "intend," "may," "will," "would," "could,"
"should," "might," "potential," or "continue" and variations or similar expressions. Readers
should not unduly rely on these forward-looking statements, which are not a guarantee of future performance. There can be no assurance
that forward-looking statements will prove to be accurate, as all such forward-looking statements involve known and unknown risks, uncertainties
and other factors which may cause actual results or future events to differ materially from the forward-looking statements. Such risks
include: the ability of Edesa to obtain regulatory approval for or successfully commercialize any of its product candidates, the risk
that access to sufficient capital to fund Edesa's operations may not be available or may be available on terms that are not commercially
favorable to Edesa, the risk that Edesa's product candidates may not be effective against the diseases tested in its clinical trials,
the risk that Edesa fails to comply with the terms of license agreements with third parties and as a result loses the right to use key
intellectual property in its business, Edesa's ability to protect its intellectual property, the timing and success of submission, acceptance
and approval of regulatory filings, and the impacts of public health crises, such as Covid-19. Many of these factors that will determine
actual results are beyond the company's ability to control or predict. For a discussion of further risks and uncertainties related to
Edesa's business, please refer to Edesa's public company reports filed with the U.S. Securities and Exchange Commission and the British
Columbia Securities Commission. All forward-looking statements are made as of the date hereof and are subject to change. Except as required
by law, Edesa assumes no obligation to update such statements.
Contact
Gary Koppenjan
Edesa Biotech, Inc.
(289) 800-9600
investors@edesabiotech.com
Exhibit 99.2
Edesa Biotech Secures $10 Million Credit Facility
with Company Founder
| · | Revolving Line of Credit to Support Completion of Government-Funded ARDS
Study |
TORONTO, ON / ACCESSWIRE / October 12, 2023 / Edesa Biotech, Inc. (Nasdaq:EDSA)
(“Edesa”, or the “Company”), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related
diseases, today announced it has entered into a binding commitment letter in respect of a $10 million revolving credit facility agreement
with Dr. Par Nijhawan, MD, the Company’s Chief Executive Officer and Founder. The binding commitment letter was executed in parallel
with a C$23 million commitment from the Government of Canada to support a pivotal Phase 3 clinical study of the Company’s first-in-class
therapeutic candidate.
Stephen Lemieux, Chief Financial Officer of the Company, said that
the credit facility will be an important part of the Company’s growth strategy, and in particular, its development and commercialization
plans for EB05 (paridiprubart), a monoclonal antibody that Edesa is developing as a treatment for a severe form of respiratory failure
known as Acute Respiratory Distress Syndrome (ARDS).
“We greatly appreciate this vote of confidence from our Founder,
and the attractive terms of the agreement,” said Mr. Lemieux. “With this financial milestone and the funding commitment from
the Government of Canada, we will be in a significantly stronger position to move forward toward the completion of our pivotal Phase 3
study of EB05 and prepare for potential approval.”
The binding commitment letter with Dr. Nijhawan provides for a revolving
line of credit in the amount of up to $10 million, with $3.5 million available immediately upon the execution of the definitive agreement
for the credit facility. Advances under the revolving credit facility will be subject to compliance with all applicable laws, and tied
to a borrowing base consisting of eligible grant reimbursement receivables, future potential license fee receivables and any other accounts
receivable. The binding commitment letter provides for an interest rate of the CIBC US Base-Interest Rate plus 300 bps and a maturity
date of March 31, 2026. The availability of the credit facility will be subject to finalization and execution of a definitive credit agreement
and related documents.
“I’m pleased to provide both financial support and leadership
to the company as it builds on its recent operational and clinical successes,” said Dr. Nijhawan. “Edesa has a strong development
pipeline and I’m confident that we can continue to successfully execute on our plans to commercialize innovative drug therapies
for large, underserved patient populations.”
Additional details on the revolving credit facility will be outlined
in the Company’s Current Report on Form 8-K, which the Company expects to file with the U.S. Securities and Exchange Commission
and on the SEDAR+ system in Canada.
The entering into of the binding commitment letter with respect to
the credit facility constitutes a “related party transaction” within the meaning of Multilateral Instrument 61-101 –
Protection of Minority Securityholders in Special Transactions. The Company will file a material change report less than 21 days
before the credit facility will be entered into, which shorter period is necessary in the circumstances in order for the Company to access
working capital in the short term to continue its development and commercialization plans.
About Edesa Biotech, Inc.
Edesa Biotech, Inc. (Nasdaq: EDSA) is a clinical-stage biopharmaceutical
company developing innovative ways to treat inflammatory and immune-related diseases. The Company’s most advanced drug candidate
is EB05 (paridiprubart), a monoclonal antibody developed for acute and chronic disease indications that involve dysregulated innate immune
responses. Edesa is currently evaluating EB05 in a Phase 3 study as a potential treatment for Acute Respiratory Distress Syndrome (ARDS),
a life-threatening form of respiratory failure. In addition, Edesa is developing an sPLA2 inhibitor, EB01 (daniluromer), as a topical
treatment for chronic Allergic Contact Dermatitis (ACD), a common occupational skin condition. The Company has also received regulatory
approval to conduct a Phase 2 trial its EB06 monoclonal antibody as a treatment for vitiligo, a life-altering autoimmune disease that
causes skin to lose its color in patches. Edesa is also planning to file an investigational new drug application for a future Phase 2
study of paridiprubart for systemic sclerosis (scleroderma), an autoimmune rheumatic disorder that causes fibrosis, (scarring/hardening)
of skin and internal organs such as the lungs, heart and kidneys. Sign up for news alerts. Connect with us on Twitter and
LinkedIn.
Edesa Forward-Looking Statements
This press release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements may be identified by the use of words such
as "anticipate," "believe," "plan," "estimate," "expect," "intend," "may,"
"will," "would," "could," "should," "might," "potential," or "continue"
and variations or similar expressions. Readers should not unduly rely on these forward-looking statements, which are not a guarantee of
future performance. There can be no assurance that forward-looking statements will prove to be accurate, as all such forward-looking statements
involve known and unknown risks, uncertainties and other factors which may cause actual results or future events to differ materially
from the forward-looking statements. Such risks include: the ability of Edesa to finalize and execute the definitive credit agreement
related to the $10 million credit facility, the final terms of the credit facility, the ability of Edesa to obtain regulatory approval
for or successfully commercialize any of its product candidates, the risk that access to sufficient capital to fund Edesa's operations
may not be available or may be available on terms that are not commercially favorable to Edesa, the risk that Edesa's product candidates
may not be effective against the diseases tested in its clinical trials, the risk that Edesa fails to comply with the terms of license
agreements with third parties and as a result loses the right to use key intellectual property in its business, Edesa's ability to protect
its intellectual property, the timing and success of submission, acceptance and approval of regulatory filings, and the impacts of public
health crises, such as Covid-19. Many of these factors that will determine actual results are beyond the company's ability to control
or predict. For a discussion of further risks and uncertainties related to Edesa's business, please refer to Edesa's public company reports
filed with the U.S. Securities and Exchange Commission and the British Columbia Securities Commission. All forward-looking statements
are made as of the date hereof and are subject to change. Except as required by law, Edesa assumes no obligation to update such statements.
Contact
Gary Koppenjan
Edesa Biotech, Inc.
(805) 488-2800
investors@edesabiotech.com
v3.23.3
X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
+ Details
Name: |
dei_AmendmentFlag |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
+ Details
Name: |
dei_DocumentPeriodEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
+ Details
Name: |
dei_DocumentType |
Namespace Prefix: |
dei_ |
Data Type: |
dei:submissionTypeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
+ References
+ Details
Name: |
dei_EntityAddressAddressLine1 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Definition
+ References
+ Details
Name: |
dei_EntityAddressCityOrTown |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionISO 3166-1 alpha-2 country code.
+ References
+ Details
Name: |
dei_EntityAddressCountry |
Namespace Prefix: |
dei_ |
Data Type: |
dei:countryCodeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCode for the postal or zip code
+ References
+ Details
Name: |
dei_EntityAddressPostalZipCode |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the state or province.
+ References
+ Details
Name: |
dei_EntityAddressStateOrProvince |
Namespace Prefix: |
dei_ |
Data Type: |
dei:stateOrProvinceItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityCentralIndexKey |
Namespace Prefix: |
dei_ |
Data Type: |
dei:centralIndexKeyItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate if registrant meets the emerging growth company criteria.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityEmergingGrowthCompany |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
+ Details
Name: |
dei_EntityFileNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:fileNumberItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
+ References
+ Details
Name: |
dei_EntityIncorporationStateCountryCode |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarStateCountryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityRegistrantName |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityTaxIdentificationNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:employerIdItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLocal phone number for entity.
+ References
+ Details
Name: |
dei_LocalPhoneNumber |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 13e -Subsection 4c
+ Details
Name: |
dei_PreCommencementIssuerTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 14d -Subsection 2b
+ Details
Name: |
dei_PreCommencementTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTitle of a 12(b) registered security.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b
+ Details
Name: |
dei_Security12bTitle |
Namespace Prefix: |
dei_ |
Data Type: |
dei:securityTitleItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the Exchange on which a security is registered.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1
+ Details
Name: |
dei_SecurityExchangeName |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarExchangeCodeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Section 14a -Number 240 -Subsection 12
+ Details
Name: |
dei_SolicitingMaterial |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
+ References
+ Details
Name: |
dei_TradingSymbol |
Namespace Prefix: |
dei_ |
Data Type: |
dei:tradingSymbolItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Securities Act -Number 230 -Section 425
+ Details
Name: |
dei_WrittenCommunications |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
Edesa Biotech (NASDAQ:EDSA)
過去 株価チャート
から 8 2024 まで 9 2024
Edesa Biotech (NASDAQ:EDSA)
過去 株価チャート
から 9 2023 まで 9 2024